Litigation

Recent Posts

Amylin Sues Eli Lilly Over Diabetes Drug Development Deal
Posted on 17 May 2011 by LexisNexis Litigation Resource Community Staff

INDIANAPOLIS - (AP) Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim... Read More

Glaxo Adds Safety Restrictions To Avandia Label
Posted on 9 Feb 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) GlaxoSmithKline PLC said Monday it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack. The Food and Drug Administration... Read More

Illinois Jury Finds For Takeda In Actos Bladder Cancer Trial
Posted on 16 May 2014 by Tom Moylan

CHICAGO — (Mealey’s) An Illinois state court jury on May 15 returned a defense verdict in an Actos bladder cancer death case after four weeks of testimony ( In Re: Actos Litigation , No. 11 L 010011, Diane Whitlatch, et al. v. Takeda Pharmaceuticals... Read More

2 Attorneys Settle Their Avandia Cases In Federal, State Courts
Posted on 10 May 2010 by Tom Moylan

PHILADELPHIA — (Mealey’s) Two attorneys have settled their Avandia personal injury cases in federal and state courts with defendant GlaxoSmithKline plc, a source told Mealey Publications May 10. According to the source, W. Mark Lanier of... Read More

Nevada State Court Jury Returns Defense Verdict In 2-Plaintiff Actos Cancer Trial
Posted on 23 May 2014 by Tom Moylan

LAS VEGAS — (Mealey's) A Nevada state court jury on May 22 returned a unanimous defense verdict in a 32-day, two-plaintiff Actos bladder cancer trial, but two plaintiff attorneys say they will seek a new trial because they believe their objections... Read More

2nd Circuit Reject Overpromotion Exception To Learned Intermediary In Zyprexa Case
Posted on 16 Jul 2010 by Tom Moylan

NEW YORK - (Mealey's) A Second Circuit U.S. Court of Appeals panel on July 16 ruled that a Zyprexa multidistrict litigation plaintiff failed to show that alleged overpromotion of the atypical antipsychotic drug by manufacturer Eli Lilly and Co. misled... Read More

A Word Change Here And There and Voila! GlaxoSmithKline Has Itself 33 New Avandia Experts
Posted on 17 Aug 2010 by Tom Moylan

So you saw the words "$2.36 billion," "settlement," and "Avandia" used in the same sentence and you think the litigation is over? Well, the old gal's still kicking and nowhere was that more apparent that in GSK's... Read More

Maryland Jury Awards $1.7 Million In 2nd Actos Bladder Cancer Case
Posted on 26 Sep 2013 by Tom Moylan

BALTIMORE — (Mealey’s) A Maryland state court jury on Sept. 26 awarded $1.76 million in the second Actos bladder cancer case to go to trial ( An v. Takeda Pharmaceuticals America, Inc. , No. 24-C12003565, Md. Cir., Baltimore City). ( Verdict... Read More

California Appeals Court Reinstates $6.5 Million Actos Verdict; Expert Back In
Posted on 17 Jul 2015 by Tom Moylan

LOS ANGELES — (Mealey’s) A California appeals court panel on July 16 reinstated a $6.5 million Actos bladder cancer verdict, finding that the trial court erred in excluding the plaintiffs’ causation expert in a post-verdict ruling (... Read More

97 Federal Cases Alleging Cancer From Diabetes Drugs Centralized In MDL
Posted on 27 Aug 2013 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) Ninety-seven federal lawsuits in which plaintiffs allege that three incretin-based diabetes drugs caused their pancreatic cancer were centralized Aug. 26 by a federal judicial panel into a multidistrict litigation... Read More

Most FDA Advisers Recommend Avandia Stay On The Market
Posted on 14 Jul 2010 by Tom Moylan

GAITHERSBURG, Md. - (Mealey's) A majority of Food and Drug Administration advisers voted July 14 to keep Avandia on the market but split on whether the anti-diabetes drug made by GlaxoSmithKline PLC (GSK) should carry additional warnings about its... Read More

Preemption Summary Judgment Granted In Incretin-Mimetic Multidistrict Litigation
Posted on 11 Nov 2015 by Tom Moylan

SAN DIEGO — (Mealey’s) The California federal judge overseeing the incretin mimetic multidistrict litigation on Nov. 9 granted summary judgment to five makers or promoters of the diabetes drugs, finding clear evidence that the Food and Drug... Read More